Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (906)	2/13/1999 7:08:00 PM
From: Doug Bean	Read Replies (1) \| Respond to of 1837

Okay, Now i am confused. I am under the impression that phase III studies have been done for the purposes that DRMD is submitting the NDA. Is this right or wrong. If not what was the last double blind study that we waited for? If it was not a phaseIII . Could the FDA then say something like " well we like the look of the NDA so far but would like to see further studies done" Would they be asking then for a phase III or something else? I know DRMD is trying to blow this by for a very narrow purpose and they have compeleted satisfactory studies wherein it worked well. My concern is , I understand that AHP is developing their own conjugated estrogen and further stalling by the FDA could possibly make all this a mute point if it goes on for another year or more. CRDoug